首页 | 本学科首页   官方微博 | 高级检索  
检索        

一家系的2例儿童法布雷病诊断及治疗报道并文献复习题录
引用本文:于春梅,马凯,金瑞峰,刘勇.一家系的2例儿童法布雷病诊断及治疗报道并文献复习题录[J].国际医药卫生导报,2023,29(1):119.
作者姓名:于春梅  马凯  金瑞峰  刘勇
作者单位:山东大学附属儿童医院 济南市儿童医院神经内科,济南 250022
摘    要:目的对2例(表兄弟)以神经性疼痛为主要临床表现的法布雷病家系进行调查, 探讨法布雷病的临床特点、基因突变及治疗情况。方法先证者, 男, 11岁, 因双脚趾疼痛2年余于2021年5月在济南市儿童医院就诊;其表哥, 男, 13岁, 因脚趾末端烧灼样疼痛1年于2021年7月在济南市儿童医院就诊。抽取先证者及父母外周血, 采用LR-PCR+Ⅱ代测序方法, 确定家系突变基因位点。给予酶替代治疗, 该2例患儿均给予阿加糖酶β 1.0 mg/kg, 每2周静脉输注1次。随访1年回顾分析2例患儿的临床表现、诊疗过程。结果 2例患儿治疗3~4个月肢端疼痛缓解, 半年复查三己糖酰基鞘脂醇的衍生物(Lyso-GL-3)均明显降低(先证者Lyso-GL-3结果为2.30 μg/L, 其表哥Lyso-GL-3结果为1.30 μg/L), GLA基因检测发现c.10801082delTGG半合子突变, 变异来源均为母亲。治疗1年2例患儿临床症状均缓解, 无复发, 血浆α-半乳糖苷酶A(α-Gal A)活性恢复正常。结论分析儿童法布雷病的临床特征、基因检测及治疗原则, 以期为儿童法布雷病临床诊...

关 键 词:法布雷病  α-半乳糖苷酶A  基因突变  酶替代治疗

Diagnosis and treatment of two children with Fabry disease in a family and literature review
Yu Chunmei,Ma Kai,Jin Ruifeng,Liu Yong.Diagnosis and treatment of two children with Fabry disease in a family and literature review[J].International Medicine & Health Guidance News,2023,29(1):119.
Authors:Yu Chunmei  Ma Kai  Jin Ruifeng  Liu Yong
Institution:Department of Neurology,Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China
Abstract:Objective To investigate the clinical characteristics, gene mutation, and treatment of Fabry disease in two children from a family with neuropathic pain as the main clinical manifestation. Methods The proband, an 11-year-old boy, was diagnosed with pain in both toes for more than 2 years in Jinan Children's Hospital in May 2021. His cousin, a 13-year-old boy, was diagnosed due to burning pain at the end of his toe for one year in Jinan Children's Hospital in July 2021. Peripheral blood samples were collected from the proband and his parents. LR-PCR and generation Ⅱ sequencing were used to determine the mutation gene locus in the pedigree. The clinical manifestation, diagnosis and treatment process of 2 cases were retrospectively analyzed after 1 year follow-up of enzyme replacement therapy. Results The activity of α-galactosidase A (α-Gal A) was significantly decreased in both cases. The detection of GLA gene showed c.1080_1082delTGG hemizygous mutation, all of which originated from the mother. After one year of treatment, the clinical symptoms in both cases were relieved without recurrence, and the activity of α-Gal A in plasma returned to normal. Conclusion We investigate the clinical characteristics, gene detection, and therapeutic principle of children with Fabry disease, to provide references for clinical diagnosis and treatment of Fabry disease in children.
Keywords:Fabry disease  α-galactosidase A  Gene mutation  Enzyme replacement therapy    
点击此处可从《国际医药卫生导报》浏览原始摘要信息
点击此处可从《国际医药卫生导报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号